Gene therapy for diabetic macular edema in adults
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a gene therapy called RGX-314 for people with diabetic macular edema that affects the center of the vision. If you have had previous treatment and still have swelling, this study may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 1 or type 2 diabetes with swelling in the center of your retina from diabetic macular edema.
- Your vision in the study eye is between 20/32 and 20/320 (some vision loss but not complete blindness).
- You have had treatment with aflibercept (Eylea) that helped your vision.
- Your blood sugar control is fairly good (HbA1c of 12% or lower).
- You are not a woman who could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage (Phase 1) study tests a new gene therapy to improve vision for adults with diabetic macular edema. It mainly looks at whether the treatment can be safely given and may help your vision over time.
This trial tests a gene therapy for diabetic macular edema (DME), a condition where fluid builds up in the central part of the eye's retina. It aims to improve vision and reduce the need for frequent eye injections.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This trial tests a more frequent dosing of an eye injection called pegaptanib (Macugen) to see if it can quickly reduce swelling in the retina caused by diabetes and improve vision. It is for people with diabetic macular edema who have some vision loss.
This study tests a new gene therapy called LX111 for diabetic macular edema (DME) that has not improved enough with previous injections. It aims to see if a single treatment can reduce swelling and improve vision.
This trial tests a one-time gene therapy injection into the eye for adults with diabetic macular edema (DME), a condition where fluid builds up in the retina and blurs vision. The goal is to reduce the need for frequent eye injections and help maintain vision over time.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.